On January 12, 2021 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") reported that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, "lenvatinib") will be given at the Gastrointestinal Cancers Symposium Virtual Meeting, from January 15 to 17, 2021 (Press release, Eisai, JAN 12, 2021, View Source [SID1234574984]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
At this symposium, regarding the lenvatinib monotherapy, the real-world effectiveness among unresectable hepatocellular carcinoma (HCC) patients treated in United States clinical practices (Abstract No: 273), as well as the results of a post hoc analysis of patients with unresectable HCC who progressed to the Child-Pugh B stage in the Phase 3 REFLECT study (Abstract No: 298), will be presented.
In addition, the data to be presented regarding the combination therapy of lenvatinib plus pembrolizumab (product name: KEYTRUDA), the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada), are results from the biliary tract cancer cohort (Abstract No: 321), the colorectal cancer cohort (Abstract No: 94), and the gastric cancer cohort (Abstract No: 230) of the basket-type Phase 2 LEAP-005 clinical study for 6 types of previously treated advanced solid tumors.
In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.
Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. Eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.
This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
The full list of Eisai presentations are below.
Product / Compound
Abstract No. Title / Scheduled Date and Time (local time: Eastern Standard Time)
Lenvatinib 273
Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients treated in United States clinical practices
January 15 (Fri)
Lenvatinib 298
Post hoc analysis in patients (pts) with unresectable hepatocellular carcinoma (uHCC) who progressed to Child-Pugh B (CPB) liver function in the phase 3 REFLECT study of lenvatinib (LEN)
January 15 (Fri)
Lenvatinib + pembrolizumab 321
Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study
January 15 (Fri)
Lenvatinib + pembrolizumab 94
LEAP-005: A phase 2, multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: results from the colorectal cancer cohort
January 15 (Fri)
Lenvatinib + pembrolizumab 230
LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: results from the gastric cancer cohort
January 16 (Sat), 4:30 PM-5:15 PM (Accepted in poster highlight session)